Acurx Pharmaceuticals (ACXP) Misses Q4 EPS by 12c

Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q4 EPS of ($0.37), $0.12 worse than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Acurx Pharmaceuticals (ACXP) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance